| Name | NGB 2904,N-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyl]-9H-fluorene-2-carboxamide |
|---|---|
| Synonyms |
NGB 2904 HYDROCHLORIDE
Ngb-2904 |
| Description | NGB 2904 is an orally active and selective dopamine (DA) D3 receptor antagonist. NGB 2904 can be used for the research of cocaine addiction[1]. |
|---|---|
| Related Catalog | |
| Target |
D3 Receptor |
| In Vivo | NGB 2904 (0.1~5 mg/kg; i.p.) significantly loweres the break-point for cocaine self-administration behavior reinforced under progressive-ratio conditions and significantly inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats extinguished from daily cocaine self-administration[1]. NGB 2904 (0~10 mg/kg; i.p.) administered 30 min prior to the beginning of daily cocaine self-administration sessions has no significant effect on cocaine self-administration behavior at a unit cocaine reinforcement dose of 0.5 mg/kg/infusion compared to vehicle-treated animals. NGB 2904 (0.1 and 1 mg/kg) pretreatment significantly inhibits the enhanced brain stimulation reward produced by 2 mg/kg, but not by 10 mg/kg, of cocaine. NGB 2904 pretreatment produces a significant attenuation of this cocaine-triggered reinstatement of drug-seeking[1]. Animal Model: Male Long–Evans rats (250–300 g)[1] Dosage: 0.1~5 mg/kg Administration: I.p.; Result: Significantly lowered the break-point for cocaine self-administration behavior reinforced under progressive-ratio conditions and significantly inhibited cocaine-triggered reinstatement of drug-seeking behavior in rats extinguished from daily cocaine self-administration. |
| References |
| Boiling Point | 708.8ºC at 760 mmHg |
|---|---|
| Molecular Formula | C28H30Cl3N3O |
| Molecular Weight | 530.91600 |
| Flash Point | 382.4ºC |
| Exact Mass | 529.14500 |
| PSA | 35.58000 |
| LogP | 7.09260 |
| Vapour Pressure | 2.41E-20mmHg at 25°C |